Loading...

TARBP2-Enhanced Resistance during Tamoxifen Treatment in Breast Cancer

Tamoxifen is the most widely used hormone therapy in estrogen receptor-positive (ER+) breast cancer, which accounts for approximately 70% of all breast cancers. Although patients who receive tamoxifen therapy benefit with respect to an improved overall prognosis, resistance and cancer recurrence sti...

Full description

Saved in:
Bibliographic Details
Published in:Cancers (Basel)
Main Authors: Wang, Ming-Yang, Huang, Hsin-Yi, Kuo, Yao-Lung, Lo, Chiao, Sun, Hung-Yu, Lyu, Yu-Jhen, Chen, Bo-Rong, Li, Jie-Ning, Chen, Pai-Sheng
Format: Artigo
Language:Inglês
Published: MDPI 2019
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6406945/
https://ncbi.nlm.nih.gov/pubmed/30759864
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11020210
Tags: Add Tag
No Tags, Be the first to tag this record!